Research Article
The Clinical Values of Serum Markers in the Early Prediction of Hepatocellular Carcinoma
Table 5
The dynamic change of serum markers concentrations before and after HCC occurred.
| | Markers | Starting point (hepatic cirrhosis) | End point (HCC) | values | values | | Statistical description | | Statistical description |
| | ALB (g/l) | 17 | 32 (25–43) | 17 | 33 (26–42) | −0.166 | 0.868 | | TBIL (μmol/L) | 17 | 21 (4.8–49.5) | 17 | 19.6 (9.3–39.2) | −1.154 | 0.248 | | ALT (U/L) | 17 | 58 (20–253) | 17 | 28.5 (16–262) | −1.895 | 0.058 | | PLT (109/L) | 17 | 79 (29–165) | 17 | 61.5 (34–225) | −0.762 | 0.446 | | PT(s) (s) | 17 | 13.2 (11–15) | 17 | 13 (11.3–15.7) | −0.719 | 0.472 | | PT(a) (%) | 17 | 75.3 (64.1–98.7) | 17 | 75.1 (61.7–100.6) | −1.894 | 0.058 | | AFP (ng/mL) | 17 | 74.6 (2.34–469.9) | 17 | 136.2 (2.96–1501) | −0.152 | 0.879 | | GP73 (ng/mL) | 17 | 194.6 (66.12–350) | 17 | 154.2 (13.14–275.4) | 2.212 | 0.041 | | AFP-L3 (ng/mL) | 17 | 8.8 (0.12–77.45) | 17 | 28.8 (0.15–361.5) | −0.544 | 0.586 | | AFP-L3/AFP ratio | 17 | 0.09 (0.03–0.43) | 17 | 0.10 (0.05–0.50) | −0.848 | 0.408 |
|
|
Starting point: start time of this study; end point: the time the patients were diagnosed HCC; : number of patients.
|
